Larissa Prata

EBioMedicine · 2019

⊕ Open access · CC-BY

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

▲ 1,368

Aging Cell · 2019

⊕ Open access · CC-BY

Targeting senescent cells alleviates obesity‐induced metabolic dysfunction

▲ 687

EBioMedicine · 2023

⊕ Open access · CC-BY

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

▲ 286

EBioMedicine · 2022

⊕ Open access · CC-BY

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans

▲ 96

Aging · 2021

⊕ Open access · CC-BY

SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3

▲ 90

EBioMedicine · 2020

⊕ Open access · CC-BY

Corrigendum to ‘Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease’ EBioMedicine 47 (2019) 446–456

▲ 59

Cell Metabolism · 2022

⊕ Open access · OA

Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity

▲ 52

Journal of the American Geriatrics Society · 2021

⊕ Open access · CC-BY

Fisetin for COVID ‐19 in skilled nursing facilities: Senolytic trials in the COVID era

▲ 51

Cell Metabolism · 2025

⊕ Preprint · OA

Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice

▲ 19

Journal of Internal Medicine · 2025

⊕ Open access · OA

Senotherapeutics for metabolic disease and diabetic complications

▲ 5

Innovation in Aging · 2020

⊕ Open access · CC-BY

Effect of Combined Dasatinib and Fisetin Treatment on Senescent Cell Clearance in Monkeys

▲ 2